Major Overhang for ImmunoCellular (IMUC) Removed with CIRM Grant - Roth Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500, Nasdaq advance as soft inflation tempers Fed rate-hike bets
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise on stalled US-Iran talks and tight fuel markets
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
- HPE raises networking revenue outlook, secures $1.2B Vultr order
ImmunoCellular Therapeutics Awarded $19.9 Million Grant from California Institute for Regenerative Medicine (CIRM) to Fund ICT-107 Phase 3 Registration Program in Glioblastoma
September 24, 2015 1:52 PM EDTLOS ANGELES, Sept. 24, 2015 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today announced that the governing Board of the California Institute for Regenerative Medicine (CIRM), California's stem cell agency, has awarded the Company $19.9 million to support the ICT-107 phase 3 registration trial in patients with newly diagnosed glioblastoma. The $19.9 million was granted under the CIRM 2.0 program, a comprehensive collaborative initiative designed to accelerate the development of stem cell-based treatments for people with unmet medical needs. ICT-107 qualified for grant consideration on the basis of being specifically engineered as an immunotherapy... More
